Ketek 24,000-Patient Trial Should Be New “Benchmark” For Antibiotics

Aventis' 24,000-patient "usual care" study for Ketek should be the benchmark for investigational antibiotic safety trials, FDA Anti-Infective Drugs Advisory Committee voting consultant William Lee, MD, University of Texas Southwestern Medical School, said Jan. 8